Genetic polymorphism of C452T (T127I) in human γ-glutamyl hydrolase in a Japanese population

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 4, 2007, Pages 839-841

  Hayashi, Hideki ^a   Fujimaki, Chihiro ^a   Inoue, Kazuyuki ^b   Suzuki, Toshio ^b   Itoh, Kunihiko ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

Author keywords

glutamyl hydrolase; Childhood acute leukemia; Genetic polymorphism; Methotrexate; Rheumatoid arthritis

Indexed keywords

GAMMA GLUTAMYL HYDROLASE; METHOTREXATE;

ACUTE LEUKEMIA; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; ENZYME INACTIVATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPANESE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION DISTRIBUTION; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; GAMMA-GLUTAMYL HYDROLASE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; JAPAN; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 34147122766     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.839     Document Type: Article

References (16)

1. Evans W. E., Relling M. V., Rodman J. H., Crom W. R., Boyett J. M., Pui C. H., N. Engl. J. Med., 338, 499-505 (1998).
2. Gorlick R., Goker E., Trippett T., Waltham M., Banerjee D., Bertino J. R., N. Engl. J. Med., 335, 1041-1048 (1996).
3. Pui C. H., Evans W. E., N. Engl. J. Med., 339, 605-615 (1998).
4. Pui C. H., Campana D., Evans W. E., Lancet Oncol., 2, 597-607 (2001).
5. Andersen P. A., West S. G., O'Dell J. R., Via C. S., Claypool R. G., Kotzin B. L., Ann. Intern. Med., 103, 489-496 (1985).
6. Weinblatt M. E., Coblyn J. S., Fox D. A., Fraser P. A., Holdsworth D. E., Glass D. N., Trentham D. E., N. Engl. J. Med., 312, 818-822 (1985).
7. Goldman I. D., Lichtenstein N. S., Oliverio V. T., J. Biol. Chem., 243, 5007-5017 (1968).
8. Shane B., Vitam. Horm., 45, 263-335 (1989).
9. Zhao R., Goldman I. D., Oncogene, 22, 7431-7457 (2003).
10. Panetta J. C., Wall A., Pui C. H., Relling M. V., Evans W. E., Clin. Cancer Res., 8, 2423-2429 (2002).
11. Rhee M. S., Lindau-Shepard B., Chave K. J., Galivan J., Ryan T. J., Mol. Pharmacol., 53, 1040-1046 (1998).
12. Cheng Q., Wu B., Kager L., Panetta J. C., Zheng J., Pui C. H., Relling M. V., Evans W. E., Pharmacogenetics, 14, 557-567 (2004).
13. Stamp L., Roberts R., Kennedy M., Barclay M., O'donnell J., Chapman P., Biomed. Pharmacother., 60, 678-687 (2006).
14. Chave K. J., Ryan T. J., Chmura S. E., Galivan J., Gene, 319, 167-175 (2003).
15. Widemann B. C., Adamson P. C., Oncologist, 11, 694-703 (2006).
16. Ranganathan P., Eisen S., Yokoyama W. M., McLeod H. L., Ann. Rheum. Dis., 62, 4-9 (2003).